Equities Analysts Issue Forecasts for BioLineRx Q1 Earnings

BioLineRx Ltd. (NASDAQ:BLRX) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of BioLineRx in a research note issued to investors on Monday, March 31st. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will earn ($0.84) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for BioLineRx’s current full-year earnings is ($5.80) per share. HC Wainwright also issued estimates for BioLineRx’s Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.92) EPS and Q4 2025 earnings at ($0.99) EPS.

Separately, StockNews.com downgraded shares of BioLineRx from a “hold” rating to a “sell” rating in a research report on Tuesday, March 18th.

BioLineRx Price Performance

BLRX stock opened at $2.92 on Wednesday. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. The company has a market capitalization of $9.72 million, a P/E ratio of -0.33 and a beta of 1.39. The business has a 50 day simple moving average of $3.50 and a 200-day simple moving average of $10.62. BioLineRx has a twelve month low of $2.80 and a twelve month high of $37.22.

Institutional Trading of BioLineRx

A hedge fund recently bought a new stake in BioLineRx stock. Highbridge Capital Management LLC purchased a new position in shares of BioLineRx Ltd. (NASDAQ:BLRX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned about 50.50% of BioLineRx at the end of the most recent reporting period. 1.56% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.